喀什海绵体受损症状图(喀什做包皮手术大概费用) (今日更新中)

WASHINGTON, March 25 (Xinhua) -- Researchers at the University of Colorado (CU) and the Harvard University have found that people living at higher altitudes have a lower chance of dying from ischemic heart disease and tend to live longer than others, according to a study published this week in the Journal of Epidemiology and Community Health.They spent four years analyzing death certificates from every county in the United States. They examined cause-of-death, socio- economic factors and other issues in their research.They found that of the top 20 counties with the highest life expectancy, eleven for men and five for women were located in Colorado and Utah. And each county was at a mean elevation of 5, 967 feet above sea level. The men lived between 75.8 and 78.2 years, while women ranged from 80.5 to 82.5 years.Compared to those living near sea-level, the men lived 1.2 to 3. 6 years longer and women 0.5 to 2.5 years more."If living in a lower oxygen environment such as in our Colorado mountains helps reduce the risk of dying from heart disease it could help us develop new clinical treatments for those conditions," said Benjamin Honigman, professor of Emergency Medicine at the CU School of Medicine. "Lower oxygen levels turn on certain genes and we think those genes may change the way heart muscles function. They may also produce new blood vessels that create new highways for blood flow into the heart."Another explanation, he said, could be that increased solar radiation at altitude helps the body better synthesize vitamin D which has also been shown to have beneficial effects on the heart and some kinds of cancer.Despite these numbers, the study showed that when socio- economic factors, solar radiation, smoking and pulmonary disease were taken into account, the net effect of altitude on overall life expectancy was negligible.Still, Honigman said, altitude seems to offer protection against heart disease deaths and may also play a role in cancer development.Colorado, the highest state in the nation, is also the leanest state, the fittest state, has the fewest deaths from heart disease and a lower incidence of colon and lung cancer compared to others.

DAVOS, Switzerland, Jan. 29 (Xinhua) -- China is ready to push the decade-long Doha Round negotiations for a final success, Chinese Minister of Commerce Chen Deming said here on Saturday.Speaking at the World Trade Organization (WTO) Mini-Ministerial Meeting which brought together representatives from over 20 major trading powers, Chen said that China is ready to collaborate with other WTO members in a practical and proactive manner so as to draw a successful conclusion of the Doha Round talks by the end of 2011.A rapid conclusion of the negotiations, Chen said, will be beneficial to global economic recovery, which is to the interest of all.The commerce minister acknowledged the year 2011 as a "window of opportunity," albeit a narrow one."China will give support to the roadmap proposed by WTO Director-General Pascal Lamy," he said, adding that the country is willing to act vigorously to push forward the negotiation process.To ensure that an early final deal could be in reach, Chen said, parties should set goals in a practical manner, in accordance with the ambition level, and stick to what has been achieved as well as the Doha Development Agenda (DDA), while focusing primarily on pending issues.Held on the sidelines of the annual World Economic Forum, the WTO Mini-Ministerial Meeting is an annual event under the auspices of the Swiss Federal Government.Chen on Friday also joined discussions with his counterparts from the emerging club -- India, Brazil and South Africa, before attending the trade G7 meeting, consisting of Australia, Brazil, China, the European Union, India, Japan and the United States.

BEIJING, Feb. 1 (Xinhua) -- A plane carrying Chinese nationals who were stranded in Egypt arrived at Beijing Capital International Airport Tuesday afternoon.The plane, operated by the Air China International Corporation, arrived in Beijing at 16:50 p.m. Bejing time. The second plane, operated by Hainan Airlines, will arrive in south China's Guangzhou city later Tuesday.The two planes carry a total of 480 Chinese nationals."China has attached great importance to safety of the stranded Chinese nationals since demonstrations and protests broke out in Egypt on Jan. 28," said Chinese Foreign Ministry spokesman Hong Lei at a regular news briefing.Hong said China has taken a package of emergency measures including warning against travel and an around-the-clock hotline to provide consular protection and assistance for the Chinese nationals.The spokesman said that a working taskforce, composed of officials from China's Foreign Ministry, National Tourism Administration, Ministry of Public Security and Civil Aviation Administration, are currently working with the Chinese embassy in Cairo to provide assistance to stranded Chinese in Egypt and to try to facilitate their early return to China.

TIANJIN, April 16 (Xinhua) -- As China tries to establish a universal medicare umbrella, its first move to offer treatment to all the hemophilia patients in the country is to know their population and where they are.China's national hemophilia information management center registered 7,980 cases nationwide since its establishment last year in a bid to provide reference for making national treatment policies and medicine production quota, said the center officials Saturday.Yang Renchi with the center and the Chinese Academy of Medical Sciences, said that the patient information database will help the government make hemophilia-related medical and social welfare policies, optimize resources and guide the manufacturing of drugs such as coagulation factor VIII.The information center, created by the Ministry of Health, is located in the Blood Diseases Hospital of the Chinese Academy of Medical Sciences in the port city Tianjin in north China.Hemophilia is a rare genetic bleeding disorder that prevents the blood from clotting properly, resulting in easy bruising and prolonged bleeding from trauma. Lack of treatment can lead to permanent disabilities or even death.China is estimated to have roughly 100,000 hemophilia patients."Be inspired; get involved in Treatment for All" is the theme for the 22nd World Hemophilia Day, which falls on Sunday, April 17."A necessary precondition for 'Treatment for All' is to know the clinical information and location of each case," said Yang, "and this is exactly what the information system does."In addition, China plans to establish hospital-based provincial hemophilia management centers within five years across the country to register and monitor patients and standardize disease diagnosis and treatment under the information system.SHORTAGE OF DRUGSBlood-derived coagulation factor VIII and recombinant coagulation factor VIII are two effective drugs which are vital for hemophiliacs. However, the drugs are expensive and produced in limited quantities, a difficulty which hundreds of thousands of hemophiliacs in China have to confront.According to Yang, the minimum dose of coagulation factor VIII for prevention of bleeding episodes is two international units (IU) per kg of weight a day. A 50-kg hemophilia patient needs at least 36,500 IU of factor VIII every year to prevent bleeding."Each IU of blood-derived coagulation factor VIII costs about 3 yuan(0.46 U.S. dollars) and the annual cost is almost 120,000 yuan. The recombinant one is almost twice the price," said Yang.Only four drug firms are qualified to manufacture blood-derived coagulation factor VIII in China. The national output in 2010 was 400,000 vials (200 IU per vial) which means 80 million IU for the entire country.Wu Runhui, a hematology specialist with the Beijing Children's Hospital, said that the minimum dose is only for the prevention of bleeding episodes which are required to keep the patient alive. For the hemophiliac to live a regular lifestyle, 3,000 IU per kilo a year is needed, which would cost half a million yuan a year."Even in the most developed countries, a hemophiliac cannot survive without supportive medical policies and social welfare system," said Wu.

WASHINGTON, March 22 (Xinhua) -- A long-term study by Greek researchers has shown the effectiveness of replacing bone marrow, purposely destroyed by chemotherapy, with autologous (self) stem cells in treating people with aggressive forms of multiple sclerosis (MS).The study was published on Tuesday in Neurology, the medical journal of the American Academy of Neurology.For the treatment, chemotherapy drugs are used to kill all of the patient's blood cells, including the immune cells that are believed to be attacking the body's own central nervous system. Bone marrow stem cells removed from the patient are purified and transplanted back into the body, which saves life by replacing the blood cells and also is proposed to "reboot" the immune system.A human embryonic stem cell line derived at Stanford University is seen in this handout photo released to Reuters by the California Institute for Regenerative Medicine, March 9, 2009The study followed 35 people for an average of 11 years after transplant. The study involved people with rapidly progressive MS who had tried a number of other treatments for MS with little or no effect. All were severely disabled by the disease, with an average score of six on a scale of disease activity that ranges from zero being a normal neurological examination to 10 meaning death due to MS.A score of six means able to walk with a cane or crutch; a seven is mainly in a wheelchair. All had worsened by at least one point on the scale in the year prior to the transplant.After the transplants, the probability of participants having no worsening of their disease for 15 years was 25 percent. The probability was higher -- 44 percent -- for those who had active brain lesions, which are a sign of disease activity, at the time of the transplant.For 16 people, symptoms improved by an average of one point on the scale after the transplant, and the improvements lasted for an average of two years. The participants also had a reduction in the number and size of lesions in their brains. Two people (six percent) died from complications related to the transplant at two months and 2-1/2 years post-transplant.Study author Vasilios Kimiskidis, of Aristotle University in Thessaloniki, Greece, noted that more research is needed on this treatment, including studies that compare people receiving the treatment to a control group that does not receive the treatment."Keeping that in mind, our feeling is that stem cell transplants may benefit people with rapidly progressive MS," he said. "This is not a therapy for the general population of people with MS but should be reserved for aggressive cases that are still in the inflammatory phase of the disease."

来源：资阳报